Last reviewed · How we verify
NCT03581929: ABO-MEMO
Efficacy of MEMORMAX in Subjects With MCI
NA trial testing Memormax in Mild Cognitive Impairment in 50 participants. Completed in 19 December 2019.
19 December 2019
Quick facts
| Lead sponsor | Aboca Spa Societa' Agricola |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | double |
| Primary purpose | supportive care |
| Enrollment | 50 |
| Start date | 20 November 2017 |
| Primary completion | 19 December 2019 |
| Estimated completion | 19 December 2019 |
| Sites | 1 location across Italy |
Drugs / interventions tested
- Memormax
- Placebo
Conditions studied
- Mild Cognitive Impairment — all drugs for Mild Cognitive Impairment →
Sponsor
Aboca Spa Societa' Agricola — full company profile →
Who can join
55 and older, any sex, with Mild Cognitive Impairment. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a single-center, randomized, double-blinded placebo for the first 6 months of treatment in subjects with mild cognitive impairment. Open-label treatment, with all subjects receiving active treatment, for the next 6 months of study.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03581929
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Mild Cognitive Impairment
Currently open trials in the same condition.
- NCT05791994 — EVASION: Effect of VisuAl Stimulation on attentION · NA · recruiting
- NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
- NCT07220694 — Effects of Sabroxy® Supplementation on Insulin Resistance and Cognitive Function in Adults With Mild Cognitive Impairmen · NA · recruiting
- NCT06983769 — CPAP vs MAD for OSA in Patients With Cognitive Impairment. A Randomized Clinical Trial · NA · recruiting
- NCT07318038 — The Use of Rhythmic Light Therapy in Mild Cognitive Impairment · NA · recruiting
Other Aboca Spa Societa' Agricola trials
Trials by the same sponsor.
- NCT05904938 — Oral Administration of Actitan-F in Paediatric Diarrhoea · NA · unknown
- NCT05192317 — Administration of a Natural Molecular Complex in Functional Chronic Constipation · NA · unknown
- NCT05016024 — Administration of a Molecular Complex of Resins, Polysaccharides and Polyphenols in Irritable Bowel Syndrome. · NA · completed
- NCT03531372 — Mipolixin® Compared to Poliprotect® in Moderate Functional Dyspepsia and Heartburn. · NA · completed
- NCT03545724 — Effectiveness & Safety of Neofitoroid® in Hemorrhoidal Disease · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03581929 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Aboca Spa Societa' Agricola
- Last refreshed: 29 July 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03581929.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing